Sign in
Taking peoplePhase 2

Melatonin for Treatment of Delirium in Critically Ill Adult Patients

Key facts

Who runs it
Ciusss de L'Est de l'Île de Montréal
Where
Canada1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
30 people, planned
Started
1 Feb 2023
Expected to end
30 Dec 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Melatonin
  • Placebo
Record updated
23 March 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (14)Hide the full registry criteria

Who can take part

  • Patients aged 18 years or older admitted to the intensive care unit
  • Anticipated ICU stay > 48 hours
  • ICDSC score greater than or equal to 4 for a maximum of 48 hours prior to randomization

Who cannot take part

  • Use of melatonin within 24 hours prior to randomization
  • Diagnosis of delirium prior to ICU admission
  • Absolute contraindication to receive enteral medication
  • Known allergy or hypersensitivity to melatonin or to ingredients in ORA-BLEND SF®
  • Presence of severe structural brain injury (intracranial hemorrhage or traumatic brain injury), severe major neurocognitive disorder, advanced neurodegenerative disease or hepatic encephalopathy
  • Diagnosis of schizophrenia, bipolar affective disorder, psychotic depression, uremic encephalopathy or alcohol withdrawal
  • Presence of active seizures, coma, aphasia or severe intellectual disability
  • Limited short-term vital prognosis
  • Pregnancy or breastfeeding
  • Inability to understand or speak English or French
  • Total blindness

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Delirium

This trial is currently available in Canada.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this study is to determine the feasibility of conducting a randomized controlled trial (RCT) with melatonin for treatment of delirium in critically ill adult patients. From a feasibility perspective, the investigators believe that the proposed design will achieve the minimum enrollment rate necessary to conduct a future RCT on a larger scale.

The 2 groups in the trial

  • Enteral melatonin 9 mgTreatment being tested

    Melatonin 9 mg from a 1 mg/mL oral suspension of melatonin in ORA-BLEND SF® (sugar-free flavoured suspending vehicle). Final volume in the oral syringe will be 9 mL.

    Treatment: Melatonin

  • Enteral placeboPlacebo, for comparison

    ORA-BLEND SF® (sugar-free flavoured suspending vehicle). Final volume in the oral syringe will be 9 mL.

    Treatment: Placebo

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
DELIRE-ICU: A Randomised Controlled Feasibility Trial of Melatonin vs Placebo in the Treatment of Delirium in the Intensive Care Unit
Criteria questions
Built from NCT05713877, who can take part
Record updated
23 March 2026